Used as a linker in antibody-drug conjugates (ADCs) to connect cytotoxic agents to monoclonal antibodies. Its primary role is to enable targeted delivery of potent drugs to cancer cells by providing a stable connection that remains intact in circulation but releases the drug inside the target cell. The SPDB component allows for cleavage in the intracellular environment, particularly in the presence of high glutathione levels, which are common in tumor cells. This selective release enhances therapeutic efficacy while minimizing damage to healthy tissues. Dimethylamine-SPDB is valued for its balance between stability and efficient drug release, contributing to improved pharmacokinetics and reduced side effects in ADC-based cancer treatments.